The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood circulation.
Critically, drug absorption kinetics can be impeded by either the rate of dissolution or permeation. The dissolution rate is a limiting factor, particularly for lipophilic substances and drugs with inherently low aqueous solubility, including extended-release formulations. Permeation, on the other hand, governs the absorption rate in hydrophilic drugs, dictating their transport through lipid bilayers.
The Biopharmaceutics Classification System (BCS) stratifies drugs into four classes based on their solubility and permeability attributes. Class I compounds exhibit high solubility and permeability and are readily absorbed. Class II drugs are hindered by poor solubility, Class III by diminished permeability, and Class IV face absorption challenges attributed to both low solubility and permeability. Examples include diltiazem (Class I), nifedipine (Class II), insulin (Class III), and taxol (Class IV).
A critical pharmacokinetic parameter, dissolution rate, is also quantified as the rate at which a drug transitions from a solid state to a solubilized form within a given solvent under controlled conditions. Solubility challenges substantially impact the dissolution rate, notably for compounds with aqueous solubility below 1-2 mg/ml within the gastrointestinal pH range of 2 to 8. Nevertheless, drugs such as cisapride overcome low intrinsic solubility through a swift dissolution rate and small therapeutic dose, ensuring sufficient absorption within the gastrointestinal transit period. Dissolution dynamics correlate more with overall drug absorption and bioavailability than absolute solubility.
The drug absorption process from solid oral dosage forms, like tablets or capsules, into the systemic circulation involves sequential events.
Firstly, drug disintegration occurs, breaking the solid drug into smaller particles.
Next, dissolution takes place, causing these smaller drug particles to dissolve in bodily fluids like gastrointestinal fluids.
The dissolved drug then permeates the intestinal membrane, facilitating absorption into the bloodstream.
Notably, the drug absorption process can be either dissolution rate-limited or permeation rate-limited.
Dissolution is a rate-limiting step for lipophilic or poorly aqueous soluble drugs, while it is intentionally controlled in the extended-release formulations. Meanwhile, permeation through lipid membranes is the rate-limiting step for hydrophilic drugs.
The biopharmaceutics classification system categorizes drugs into four classes based on absorption patterns.
Class I drugs are well absorbed orally; class II drugs face limitations due to low solubility; class III drugs exhibit poor permeability, and class IV drugs with both low solubility and permeability experience poor absorption.
繁體中文
